LTB4 antagonist 1
LTB4 antagonist 1, a carboxamide-acid compound, is a potent Leukotriene B4 (LTB4) antagonist with an IC50 of 288 nM. LTB4 antagonist 1 has significant anti-inflammatory properties.
For research use only. We do not sell to patients.
- CAS No.: 2929239-84-7
- Formula: C26H23NO6
- Molecular Weight:445.46
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Leukotriene Receptor Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
LTB4 |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:The model of podal edema with carrageenan in rats[1]
-
Dosage:30 mg/kg
-
Administration:Orally; single dose
-
Result:After 1 h, a significant anti-inflammatory activity was observed (percentage inhibition of the edema: 39.7%) on carrageenan compared to the control group.
After 2 h, the anti-inflammatory activity decreases sharply (16.2%).
This activity completely disappeared after 4 h under TUKEY test.
Chemical Information
-
CAS No. 2929239-84-7
-
Molecular Weight 445.46
-
Formula C26H23NO6
-
SMILES
CN(C(C1=C(OC2=CC(OCC3=CC=CC=C3)=CC=C2O1)C(O)=O)=O)CCC4=CC=CC=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)